['hematopoietic/lymphoid cancer', 'nausea and vomiting', 'unspecified adult solid tumor, protocol specific']
['olanzapine', 'chemotherapy (cisplatin or cyclophosphamide and doxorubicin)', 'antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)']

        -  Diagnosis of malignant disease

          -  No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing
             regimen or anthracycline + cyclophosphamide [AC])

               -  Cisplatin at a dose of ≥70mg/m^2, with or without other chemotherapy agent(s) OR

               -  Anthracycline (60 mg/m^2) plus cyclophosphamide(600 mg/m^2)

          -  Age ≥18 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2

          -  Required Initial Laboratory Values ≤ 120 days prior to registration

               -  Serum Creatinine ≤2.0 mg/dL

               -  Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic
                  transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)

               -  Absolute neutrophil count (ANC) ≥1500/mm^3

          -  No nausea or vomiting ≤ 24 hours prior to registration

          -  Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women
             of childbearing potential only (per clinician discretion)

          -  No severe cognitive compromise

          -  No known history of CNS disease (e.g. brain metastases, seizure disorder)

          -  No treatment with another antipsychotic agent such as risperidone, quetiapine,
             clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned
             during protocol therapy

          -  No chronic phenothiazine administration as an antipsychotic agent (patients may
             receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)

          -  No concurrent use of amifostine

          -  No concurrent abdominal radiotherapy

          -  No concurrent use of quinolone antibiotic therapy

          -  No chronic alcoholism (as determined by the investigator)

          -  No known hypersensitivity to olanzapine

          -  No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial
             infarction within the previous six months.

          -  No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic
             agent)
      